Clinical Research Directory

Inclusion Criteria: * Patients with relapsed or refractory CD5+ NK and T-cell originated malignancies (per WHO classification 2017). * Patients with relapsed or refractory disease previously treated with two or more lines of standard chemotherapies and there is no longer any treatment option considered as assessed by the Investigator. * According to the Lugano classification, patients having lesion/nodules ≥ 1 with diameter longer than 1.5 cm for nodal lesions and longer than 1.0 cm for extranodal lesions, and the boundaries are clearly shown. * Patient has a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status. * Patients who satisfy the criteria defined in the protocol. * Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: * Has T-ALL/T-LBL or CTCL. * Patient with CNS lymphoma or any involvement of the CNS. * Patient who had a prior history of another malignancy over the last 3 years. * Patients who have used hematopoietic growth factor therapy within 14 days prior to Screening. * Patients who have had prior CAR-T or CAR-NK therapies. * Presence of uncontrolled fungal, bacterial, viral infection or other infection requiring IV antimicrobials for management * Patients with previous allogenic organ transplantation * Patients with previous diagnosis of primary immunodeficiency or currently undergoing therapy of primary immunodeficiency. * Patients with acute GvHD ≥ Grade 3 or extensive chronic GvHD within 2 weeks of lymphodepletion. * Patients with known active Hepatitis B or C * Patients with presence of Grade 2 or greater toxicity from the previous treatment.